Roth Keeps TG Therapeutics (TGTX) as 'Focus Pick' Following ASCO Presentations

Roth Capital affirms TG Therapeutics, Inc. (Nasdaq: TGTX) at Buy/Focus Pick with price target of $15 following presentation of TG-1101 and TGR-1202 data at ASCO.

Analyst Joseph Pantginis commented, We are impressed with the data and we received the same question from investors; "Did you expect the data to be this good?". The KOLs running the studies are strongly behind these clinical data, especially the safety profiles, which make the therapies amenable to combination therapy. We believe TG has delivered solid proof of concept data for both drugs. We now look to two key upcoming catalysts. Of particular note, we look forward to seeing the data from the potential "match made in heaven" combination studies; 1) '1101 + Imbruvica in advanced B-cell tumors and 2) '1101 + '1202 in advanced B-cell tumor shortly. Second, one or both of these drugs is expected to enter pivotal studies by the end of 2014.

For an analyst ratings summary and ratings history on TG Therapeutics click here. For more ratings news on TG Therapeutics click here.

TG Therapeutics closed at $6.53 yesterday.

You May Also Be Interested In

• TG Therapeutics (TGTX) Announces Additional Data Presentations for BRIUMVI in Multiple Sclerosis
• TD Cowen Resumes EQT Corp. (EQT) at Hold
• Synovus Financial (SNV) PT Lowered to $42 at Piper Sandler